Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease

NCT07404865 is registered in ClinicalTrials.gov with Vor Biopharma as lead sponsor.

NCT NCT07404865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07404865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease
Lead sponsor
Vor Biopharma
Phase
Phase 3
Overall status
Recruiting
Start date
February 26, 2026
Completion date
January 31, 2029
Enrollment
250 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjogren's disease